argenx SE

Income comes mainly from direct sales of its approved therapy, recognized once a customer takes control of the product, with a much smaller stream from collaboration and licensing arrangements that pay milestones and royalties tied to a partner's own sales. Revenue and the amounts owed to it by customers have risen together over recent years.

Its returns, margins and cash coverage sit at the upper end of its peer group on several measures at once, and the elevated returns are not explained by leverage alone. Operating income and revenue have both grown across most recent years, though net income has not been positive in every one of those years, so this peer-relative strength describes a recent trailing position rather than an unbroken run of profit. Its own account of an approved therapy expanding into more countries and more approved uses is consistent with scale coming from broadening an already-cleared product rather than from new regulatory approvals, though CompanyGraph does not measure that mechanism directly.

It depends on named outside contract manufacturers, including Lonza and Fujifilm, for the drug substance behind its therapy and for later production steps, and it licenses formulation technology from Halozyme. It says some of the raw biological materials it needs come from a single source in limited supply without naming which ones, and it says it does not intend to build its own manufacturing capability.

Patients, prescribing physicians and healthcare payors depend on it for its approved autoimmune therapy, reached through its own sales channels, specialty distributors, and, in a named region, a separate commercialization partner. A share of its direct commercial revenue is concentrated among a small number of customers it does not name.

This way of operating is shared by a large number of other companies, so the underlying business shape is not itself rare. Within that group, it sits at the upper end on several return and margin measures. It attributes this position to its antibody-engineering platforms and its patents, trade secrets and manufacturing know-how, though this is its own account of its strengths rather than a measurement of whether rivals could reproduce them.

In its own account, it names regulatory approval of new uses for its therapies, market acceptance, the capacity of the third parties that supply and manufacture for it, and its ability to recruit and keep qualified staff as the factors limiting its growth. This sits within a broader pattern common to its industry, where clearing a regulatory approval is the step that must happen before a product earns anything at all.

In its own risk disclosures, it names reliance on outside parties across research, clinical testing, raw materials, manufacturing and parts of commercialization, and says it has no internal capability to source raw materials or manufacture its own products. It says some of the raw materials it needs come from a single source in limited supply, and it discloses that a portion of its direct commercial revenue is concentrated among a small number of customers it does not name.

It operates under multiple national medicines regulators across the markets where it sells its therapy. It names exposure to tariffs and other trade barriers affecting imported branded pharmaceuticals, including the possibility of retaliatory tariffs, and it carries currency exposure from operating in several currencies besides its reporting currency. In its most recent disclosure on file, it reported no pending legal or regulatory proceedings with significant effects.